Information  X 
Enter a valid email address

Ergomed PLC Ord 1P (ERGO)

Related News

10-Jun-2022 03:11 PM

IN BRIEF: Ergomed notes robust order book and strong sales

Ergomed PLC - Guildford, England-based service provider to the biopharmaceutical industry - Reports strong start to 2022, with a robust order book and strong sales momentum. Cites the resilience of its services-based business model for this. Notes cont
29-Mar-2022 02:50 PM

EARNINGS UPDATES: Mission swings to profit; S&U doubles profit

The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: ---------- Mission Group PLC - Devon, England-based creative and marketing technology agency - Swings to pre
09-Feb-2022 11:47 AM

Ergomed buys consultancy ADAMAS for GBP25.6 million

(Alliance News) - Ergomed PLC on Wednesday said it completed the "value-enhancing" acquisition of ADAMAS Consulting Group Ltd for a cash consideration of GBP25.6 million. Ergomed shares were up 3.3% at 1,105.00 pence each on We
10-May-2021 03:25 PM

Ergomed appoints Mark Enyedy as Non-Executive Director

Pharmaceutical services company Ergomed plc announced Mark Enyedy will join the board as a non-executive director with effect from 10 June 2021. Enyedy has extensive knowledge of the biopharmaceutical sector brining more than 25 years of senior experie
23-Mar-2021 09:04 AM

Ergomed annual profit more than doubles as acquisitions boost growth

Pharmaceutical industry services provider Ergomed reported a rise in annual profit as acquisitions in the US bolstered performance. For the full Year ended 31 December 2020, pre-tax profit more than doubled to £12.6 million from £5.0 million
26-Jan-2021 09:52 AM

Ergomed sees adjusted earnings ahead of market expectations as momentum continues

Pharmaceutical industry services provider Ergomed said it expects revenue to be in line with current market expectations and adjusted earnings before interest taxes, depreciation and amortisation (EBITDA) to be ahead of current market expectations. Reve
22-Sep-2020 02:03 PM

Ergomed profit up 44% as Covid-related trials boost business

Pharmaceutical services company Ergomed posted a 44% rise in first-half profit after it won new business, including in Covid-19-related trials, and substantially boosted revenue in North America. The company also said it was planning a capital reduction,
10-Jun-2020 08:16 AM

Ergomed 'confident' performance will meet expectations

Pharmaceutical services provider Ergomed said it was confident annual performance would meet expectations after growing its order book in the second quarter and implement cost cuts to support revenue. 'Despite the impact of Covid-19 on the general
29-Jan-2020 09:34 AM

Ergomed sees earnings ahead of market forecasts following 'strong' revenue growth

Ergomed said it expected earnings to top market forecasts following a 'strong' year of revenue growth. Revenues for 2019 were expected to be in line with expectations at approximately £68m, an increase of 26% over prior year, with clinic
25-Sep-2019 02:36 PM

Ergomed swings to profit as sales jump 37%

Services provider to the pharmaceutical industry Ergomed swung to a first-half profit on the back of higher sales and wider margins. Pre-tax profit for the six months through June amounted to £4.15m, compared to a profit of £2.46m on-year. R
22-Jul-2019 09:52 AM

Ergomed sees annual earnings, revenue beating current market expectations

Pharmaceutical industry services provider Ergomed said it expected its full-year revenue and operating earnings to be ahead of current market expectations following a strong first half. For the six months through June, revenue was expected to rise 36% to
04-Jun-2019 07:48 AM

Ergomed appoints Richard Barfield as Chief Financial Officer

Pharmaceutical services provider Ergomed appointed Richard Barfield FCA as Chief Financial Officer, effective immediately. Barfield replaced Stuart Jackson, who was set to leave Ergomed to return to the energy sector, as announced earlier this year in F
16-May-2019 12:50 PM

Broker Forecast - Numis issues a broker note on Ergomed Plc

Numis today upgrades its investment rating on Ergomed Plc (LON:ERGO) to buy (from add) and raised its price target to 267p (from 190p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
16-May-2019 09:13 AM

Ergomed expects to deliver results 'materially above' market expectations following 'strong' start t

Ergomed said it was on track to deliver annual results 'materially above' market expectations following a 'strong' start to the year. The company said it now expected revenue and earnings (EBITDA) for the year ending 31 December 2019
10-Apr-2019 07:47 AM

Ergomed reports wider losses amid writedown of Haemostatix business

Pharmaceutical services provider Ergomed reported a wider loss for the year as the writedown of its Haemostatix business offset a strong performance in its services segment. For 2019, pre-tax losses widened to £10.77 from £4.45m a year earli
01-Apr-2019 08:18 AM

Ergomed industry appoints Roy Ovel as Chief Commercial Officer

Pharmaceutical services provider Ergomed industry appointed Roy Ovel as Chief Commercial Officer with immediate effect. Roy would join Ergomed's Executive team and be responsible for global sales and business development activities across the Compa
13-Feb-2019 10:18 AM

Ergomed CFO Stuart Jackson to step down

Ergomed, a pharmaceutical industry supplier, said Wednesday Stuart Jackson would be stepping down as Chief Financial Officer in the summer this year. The move comes as Jackson is set to take up a position as Chief Financial Officer of a listed entity. He
31-Jan-2019 10:07 AM

Ergomed earnings boosted by 'significant' profit growth in second half

Pharmaceutical services provider Ergomed said Thursday annual earnings were expected to meet market expectations on the back of cost cuts and a 'significant' turnaround in profits seen in the second half. Net Service fee revenues for 2018 were
19-Sep-2018 10:40 AM

Broker Forecast - Numis issues a broker note on Ergomed Plc

Numis today upgrades its investment rating on Ergomed Plc (LON:ERGO) to add (from hold) and cut its price target to 190p (from 250p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
19-Sep-2018 10:12 AM

Ergomed swings to loss as delays to projects bite

Ergomed swung to a first-half loss Wednesday as performance was impacted by delays to the start of some contracts and reductions in scope by sponsors of others. For the six months ended 30 June, pre-tax losses were £2.93m, compared with a profit of
02-Jul-2018 09:32 AM

Ergomed hires Stuart Jackson as CFO

Pharmaceutical services provider Ergomed said Monday it had appointed Stuart Jackson as Chief Financial Officer with immediate effect. Jackson has 20 years' experience at Chief Financial Officer level, having managed companies on the London, NASDAQ
28-Jun-2018 09:30 AM

Broker Forecast - Numis issues a broker note on Ergomed Plc

Numis today downgrades its investment rating on Ergomed Plc (LON:ERGO) to hold (from buy) and cut its price target to 250p (from 300p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
25-May-2018 09:05 AM

Ergomed bolsters PrimeVigilance's offering with key hire

Ergomed said Friday it had appointed Dr Michael Forstner as Head of Risk Management and Pharmacoepidemiology, bolstering its PrimeVigilance's offering. Dr Forstner is an expert in pharmacovigilance with significant experience in the planning, develo
11-Apr-2018 10:06 AM

Ergomed swings to EBITDA loss despite revenue growth

Ergomed said total revenue grew 21% to £47.6m in 2017, from £39.2m the previous year, as net service revenue jumped 36% to £39.6m. Within services, drug safety & medical information (pharmacovigilance) revenue grew 67% The firm repor
05-Mar-2018 09:17 AM

Ergomed says adjusted EBITDA to undershoot market expectations

Ergomed plc said adjusted EBITDA before R&D for 2017 is expected to be approximately £0.6m lower than current market consensus of £6m weighed by foreign exchange losses and a higher R&D expense. R&D expense is expected to be £0.3m high

a d v e r t i s e m e n t